Cardiovascular disease in Noonan syndrome

Terence W Prendiville,1 Kimberlee Gauvreau,1,2 Erica Tworog-Dube,3 Lynne Patkin,1 Raju S Kucherlapati,2,3 Amy E Roberts,1,2,4 Ronald V Lacro1,2

ABSTRACT

Background Noonan syndrome (NS), a relatively common autosomal dominant disorder with an incidence of 1 in 1000 to 2500 live births, is the most common syndromic cause of congenital heart disease after Trisomy 21.

Objective To comprehensively define the spectrum of cardiac morphology and specific clinical course of a large cohort of NS patients.

Design Retrospective, descriptive case series study.

Patients An international Harvard-based NS registry was combined with clinical data from NS patients followed at Boston Children’s Hospital, Massachusetts, USA.

Results We identified 293 patients with NS. Cardiovascular disease was seen in 81% (n=237) including pulmonary stenosis in 57%, secundum atrial septal defects in 32% and hypertrophic cardiomyopathy in 16%. A genetic mutation of the RAS-MAPK signalling pathway was identified in 62% (n=136). Genotype-phenotype associations were noted between PTPN11 mutations and atrial septal defects (p=0.001), and pulmonary stenosis (p<0.001). RAF1 mutations were associated with hypertrophic cardiomyopathy (p<0.001).

Cardiovascular outcomes that differed specifically in a NS cohort included high re-intervention rates (65%) after percutaneous balloon pulmonary valvuloplasty for valvar pulmonary stenosis. Additionally, in NS patients with hypertrophic cardiomyopathy, a clinically significant regression of hypertrophy (17%) was observed as was a markedly higher incidence of concomitant congenital heart defects (70%).

Conclusions Patients with NS have a distinct spectrum of cardiac phenotypes that may have a natural history and response to therapy atypical to that normally seen in non-syndromic heart disease. A diagnosis of NS in a patient with pulmonary stenosis or infant-onset hypertrophic cardiomyopathy would facilitate condition-specific counselling on outcome and prognosis.

INTRODUCTION

Noonan syndrome (NS) (OMIM 163950), first described in 1963, is a relatively common autosomal dominant disorder characterised by distinctive facial features including hypertelorism, ptosis and low-set ears; short stature; developmental delay of variable degree; lymphatic vessel dysplasia and cardiac defects (see figure 1).1–3 It is a genetically heterogeneous condition with an estimated incidence of 1 in 1000 to 1 in 2500 live births and is the most common syndromic cause of congenital heart disease (CHD) after Trisomy 21.4–6 It is a genetically heterogeneous condition with an estimated incidence of 1 in 1000 to 1 in 2500 live births and is the most common syndromic cause of congenital heart disease (CHD) after Trisomy 21.4–6 Gain-of-function mutations in the RAS-MAPK signalling pathway are found in up to 60% of patients with NS and resultant perturbations in developmental processes including morphological determination, organogenesis and growth.5,7

The incidence of heart disease in NS patients is reported to be as high as 82–90%.3,8–12 Patients with NS have been noted to have a suboptimal outcome to percutaneous balloon pulmonary valvuloplasty (PBPV) for valvar pulmonary stenosis (PS).13 Additionally, NS patients with a diagnosis of hypertrophic cardiomyopathy (HCM) have been historically noted to have a significantly worse survival beyond non-syndromic HCM for reasons that are not well understood.12,14,15 The aims of our study were to describe the spectrum, management and prognosis of heart disease in NS and to investigate the cohort for genotype-phenotype correlations.

METHODS

An international Harvard-based phenotype registry and DNA repository for patients with NS was...
combined with the medical records of all clinically diagnosed NS patients at Boston Children’s Hospital (BCH) before 2010. Ethical board approval was sought and provided by the BCH Institutional Review Board. Inclusion criteria required that a patient had a clinical diagnosis of NS and had at least one evaluation by a cardiologist including an echocardiogram or cardiac catheterisation delineating cardiac anatomy. Patients with a concomitant genetic diagnosis in addition to NS were excluded from the study. The data were retrospectively reviewed for descriptors of cardiac morphology, clinical course and for pathogenic mutations in the RAS-MAPK signalling pathway.

Genetic analysis
Patients who underwent genetic screening had DNA amplification and sequencing (multiplex ligation-dependent probe amplification or equivalent) from peripheral lymphocytes in one or more of the eight described genes, namely PTPN11, SOS1, RAF1, KRAS, BRAF, SHOC2, NRAS and CBL. Deletions or duplications of one or more exons of these genes were not screened for in this analysis.

Data analysis
For patients who underwent balloon dilation of the pulmonary valve, baseline characteristics were compared for those who required subsequent surgical or catheter intervention versus those who did not, using Fisher’s exact test for categorical variables and either the unpaired t test or Wilcoxon rank sum test for continuous variables. Patients who underwent genetic mutation analysis for PTPN11, SOS1, RAF1, SHOC2 or KRAS were compared by cardiac phenotype for presence or absence of any mutation within the described gene using Fisher’s exact test. A predetermined p value of 0.05 was set as the threshold of statistical significance. Kaplan-Meier survival probability estimates were generated for those patients with HCM.

RESULTS
We identified 293 patients with NS that met inclusion criteria: 133 patients from the Harvard-based phenotype registry, 114 patients from the records of BCH and an additional 46 patients present in both databases that were included only once. Genetic screening for a NS mutation had been performed in all Harvard registry patients and 50% of patients followed at BCH. The median age of the combined cohort at last follow-up was 14 years; 60% were male. There was no significant difference in the age of those followed at BCH compared to the Harvard registry but a higher prevalence of CHD was noted at BCH (85% and 77%, respectively; p=0.04). Three quarters of the combined cohort were born in the last 25 years (figure 2).

Cardiac lesions
Heart disease was identified in 81% of all patients (see figure 3). It was observed that a high proportion of those NS patients...
identified with any cardiac defect frequently had more than one isolated cardiac lesion. For example, in those NS patients with valvar PS (n=166), it was observed to be an isolated cardiac finding in 24% (n=40). The majority (76%, n=126) of NS patients with PS, however, had additional concomitant cardiac lesion(s), commonly including secundum atrial septal defects (ASDs) (n=76), HCM (n=26) or both (n=15) (see figure 4).

Valvar pulmonary stenosis
The most common congenital cardiac lesion was valvar PS (n=166, 57% of all patients). Management of valvar PS is summarised in figure 5. Surgery or PBPV was performed in 47% (n=78) of all patients with valvar PS. Of those undergoing PBPV (n=43), the median age at intervention was 6.4 months. The average initial peak pulmonary valve gradient was 65 mm Hg prior to PBPV with an average residual valvar PS gradient of 40 mm Hg. When specifically described, pulmonary valve morphology was noted as dysplastic in 86% of those patients undergoing PBPV. Of those patients who underwent PBPV as their first intervention, 65% (n=28) required further intervention (either repeat PBPV or surgery) for clinically significant residual valvar PS. The only statistically significant risk factor for re-intervention in those with valvar PS was younger median age at the time of initial PBPV (0.54 vs 0.98 years, p=0.046).

Primary surgical repair for valvar PS was performed in 35 patients with either a pulmonary valvotomy (n=28) or transanular patch (n=7), at an average age of 6.5 years. As a group, patients who had valvar PS managed with primary surgical repair reflected a cohort 17 years prior to that undergoing primary PBPV, likely an era effect in management strategy. To date, 4% of all patients (n=7) with PS have required pulmonary valve replacement at a median age of 30 years.

Hypertrophic cardiomyopathy
There were 47 NS patients diagnosed with HCM with an average age of 16.7 years (range 0.9–59.7 years) by close of study. A diagnosis of HCM was made in the first year of life in 57% (n=27). The degree of wall thickness was described as ‘severe’ echocardiographically in 38% (n=18) with complicating subaortic obstruction noted in 15% (n=7). Concomitant cardiac lesions were found in 70% (n=33) of all patients with a
diagnosis of HCM (see table 1). A RAS-MAPK signalling pathway mutation was identified in 44% (n=21) of patients (table 1).

Of all patients with HCM, a subset (17%; n=8) diagnosed in infancy had regression of ventricular wall thickness over time on serial echocardiography with normalisation of ventricular wall dimensions over an average of 3 years (range 1–8 years) and no recurrence noted at an average of 7-year follow-up. Spontaneous regression of HCM was seen in patients with mutations in PTPN11 (n=3), RAF1 (n=1), SOS1 (n=1) and BRAF (n=1).

Interventions for symptomatic HCM (defined as congestive heart failure or exercise-induced systemic hypotension) included extensive myectomy (n=4) and alcohol septal ablation of the first septal perforator (n=1).

Documented arrhythmias complicating HCM included supraventricular tachycardia in five patients. Causes of death were known for six of the seven HCM patients who died. Refractory heart failure was the primary aetiology contributing to death in five patients with a further sixth patient dying from complications related to prematurity. Of the seven patients with HCM who died, four were diagnosed with HCM in the first year of life, giving this cohort under 1 year of age (n=27) an overall 15% mortality. See figure 6 for a Kaplan–Meier estimation of survival with a diagnosis of HCM.

RAS-MAPK signalling pathway mutations

A RAS-MAPK signalling pathway mutation was screened for in 75% (n=219) of patients with identification of a pathogenic gene mutation in 62% (n=136) (see table 2). Among all NS patients screened, mutations in the gene PTPN11 were most frequently reported (41%, n=89). The subgroup of NS patients harbouring a PTPN11 mutation were at significantly higher risk of carrying a clinical diagnosis of either valvar PS (p<0.001) or secundum ASD (p=0.001). SOS1 mutations were identified in 11% (n=25). RAF1 mutations were identified in 3% (n=7) with HCM seen in six patients, making this a significant association (p<0.001). The remaining RAS-MAPK signalling pathway pathogenic mutations identified included BRAF (n=8; 4%), SHOC2 (n=3; 1%) and KRAS (n=3; 1%).

Lymphedema

We investigated the incidence of postoperative pericardial and pleural effusions in the cohort of NS patients who underwent surgical repair of either valvar PS or an ASD at BCH (n=119 operations). Pericardial effusions occurred postoperatively in 5.9% (n=7). In the same cohort, 5% of NS patients (n=6) developed clinically significant postoperative pleural effusions with one patient developing a pleural and pericardial effusion simultaneously.

DISCUSSION

This clearly defined NS cohort provides comprehensive insight into the spectrum of heart disease, cardiac management and prognosis in a large number of patients over a broad range of ages. The cardiac lesions identified are similar in prevalence to that described by others. The cardiac lesions identified are similar in prevalence to that described by others.5 10 16 17 Aortic root dilation, seen in a small minority in our cohort (5%), has been previously reported in isolated cases of NS.18–22 No patient in our cohort with aortic root dilation had vessel dissection or required surgical intervention. Atrioventricular canal defects were described in 2.1% patients. This is a smaller percentage than the 5% reported by others, although absolute numbers of patients in any cohort remain small.5 23 With regard to the theoretical potential for a higher incidence of lymphatic complications in patients with NS after cardiac surgery, postoperative rates of

Table 1: Hypertrophic cardiomyopathy in Noonan syndrome (n=47) by gene mutation

<table>
<thead>
<tr>
<th>Gene mutation</th>
<th>Total no.</th>
<th>Sex: F</th>
<th>PS</th>
<th>ASD</th>
<th>VSD</th>
<th>PDA</th>
<th>Sub-AS</th>
<th>dx &lt;1 year</th>
<th>‘Severe’ HCM</th>
<th>Regression</th>
<th>Death</th>
<th>Arrhythmia</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTPN11</td>
<td>9</td>
<td>5</td>
<td>7</td>
<td>4</td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>8</td>
<td>3</td>
<td>3</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>RAF1</td>
<td>6</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>3</td>
<td>6</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOS1</td>
<td>4</td>
<td>2</td>
<td></td>
<td>2</td>
<td></td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KRAS</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRAF</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>26</td>
<td>12</td>
<td>15</td>
<td>9</td>
<td>1</td>
<td>3</td>
<td>12</td>
<td>9</td>
<td>2</td>
<td>5</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

*Number of patients who required a catheter-based or surgical intervention for concomitant hemodynamically significant congenital heart disease.

dx<1 year: diagnosis made in the first year of life; PDA, patent ductus arteriosus; PS, pulmonary stenosis; ‘severe’ HCM, hypertrophic cardiomyopathy classified as ‘severe’ by imaging report; Sub-AS, subaortic stenosis.
Figure 6 Kaplan–Meier survival curve for patients with Noonan syndrome and hypertrophic cardiomyopathy up to 25 years of age. Numbers still at risk are shown at 5-year age intervals.

Table 2 RAS-MAPK signalling pathway mutation and incidence of cardiac defect(s)

<table>
<thead>
<tr>
<th>Gene mutation</th>
<th>Total no.</th>
<th>Sex: F</th>
<th>PS</th>
<th>ASD</th>
<th>HCM</th>
<th>VSD</th>
<th>PDA</th>
<th>MVP</th>
<th>Ao root dil</th>
<th>Sub-AS</th>
<th>AS</th>
<th>Coarct</th>
<th>TOF</th>
<th>No CHD</th>
</tr>
</thead>
<tbody>
<tr>
<td>PTPN11</td>
<td>89</td>
<td>39</td>
<td>64</td>
<td>36</td>
<td>9</td>
<td>17</td>
<td>8</td>
<td>5</td>
<td>3</td>
<td>1</td>
<td>12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOS1</td>
<td>25</td>
<td>9</td>
<td>17</td>
<td>3</td>
<td>4</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td></td>
<td>1</td>
<td>1</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRAF</td>
<td>8</td>
<td>4</td>
<td>4</td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RAF1</td>
<td>7</td>
<td>2</td>
<td>1</td>
<td>3</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KRAS</td>
<td>3</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>SHOC2 (exon 2)</td>
<td>3</td>
<td>1</td>
<td></td>
<td>3</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Unknown</td>
<td>158</td>
<td>59</td>
<td>80</td>
<td>47</td>
<td>26</td>
<td>16</td>
<td>15</td>
<td>9</td>
<td>7</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td>4</td>
<td>34</td>
</tr>
<tr>
<td>Total</td>
<td>293</td>
<td>116</td>
<td>166</td>
<td>94</td>
<td>47</td>
<td>35</td>
<td>26</td>
<td>17</td>
<td>14</td>
<td>11</td>
<td>7</td>
<td>5</td>
<td>56</td>
<td></td>
</tr>
</tbody>
</table>

Ao root dil, aortic root dilation; AS, valvar aortic stenosis; CHD, congenital heart disease; Coarct, coarctation; MVP, mitral valve prolapse; PDA, patent ductus arteriosus; PS, pulmonary stenosis; Sub-AS, subaortic stenosis; TOF, tetralogy of Fallot.
is prudent to consider this diagnosis in the differential for children presenting with CHD and any other phenotype consistent with the presentation. Careful family history and referral for genetic counselling facilitates this investigation.

There are some important limitations of our study. We presume a referral bias to BCH for NS patients with CHD. The findings in our data set may not extrapolate to individuals diagnosed with NS secondary to cascade screening of first-degree family relatives after identification of an index case. It is reasonable to assume that such identified individuals may have a milder phenotype than those who present with clinical features diagnostic of NS or with the associated clinically relevant heart disease. The disparate ages of the cohort must be factored into any interpretation of management strategies and outcomes over time. Patients who underwent genetic screening for a NS mutation were not uniformly re-screened for mutations in newly reported genes as they became clinically available.

In conclusion, we have comprehensively described the burden of cardiovascular disease in a large, clearly defined cohort of patients with NS. Focusing on the management of those with valvar PS, we noted a high re-intervention rate before PBPV. In those patients with HCM, we noted an early age of diagnosis, a high incidence of concomitant CHD and the possibility of spontaneous disease regression in a minority over time. With a deeper understanding of disease characteristics distinct to NS, clinicians will be better able to counsel families regarding prognosis and tailor therapy for optimal patient outcome.

Acknowledgements We thank Ellen McCusty & Judith Geva for assistance with database management. We would like to thank Emily Harris for assistance formatting figures. We are indebted to the dedicated patients and families with Noonan syndrome who volunteered for the Harvard Noonan syndrome research study, W. Robinson (The Noonan Syndrome Support Group) and the referring physicians.

Contributors TWP designed the study, assembled the data and wrote the drafts and revisions of the manuscript prior to submission. He is guarantor. KG provided statistical analysis for the data. ETD assisted with extracting data from the repository. We would like to thank Emily Harris for assistance with database management. We are indebted to the dedicated patients and families with Noonan syndrome who volunteered for the Harvard Noonan syndrome research study, W. Robinson (The Noonan Syndrome Support Group) and the referring physicians.

Competing interests None.

Ethics approval Boston Children’s Hospital IRB.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement Study data available to other investigators pending Institutional Review Board approval at Boston Children’s Hospital. Please contact corresponding author for further inquiries.

REFERENCES